TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis
MediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in Confirmed Disability Progression
pharmaceutical-investing Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal
pharmaceutical-investing Corbus Gets Patent Covering Use of Anabasum for the Treatment of Rare Fibrotic Diseases
pharmaceutical-investing Adamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis
Jura Announces Dismissal in Full of PEL's Appeal against certain reliefs granted in the Settlement Agreement Arbitral Award
